Hemab Therapeutics Holdings Inc

Predicción y previsión de precio de Hemab Therapeutics Holdings Inc (COAG)

$44.370

-0.328 (-0.74%)Al cierre

Predicciones de precio

1-Day Price Prediction
+1.85%
1-Week Prediction
+3.96%
1-Month Prediction
2026 Prediction
2030 Prediction

Ábrelo en la app para desbloquear previsiones a más largo plazo.

Loading chart…

Predicción y previsión de COAG por análisis de gráficos similares

Alphio's COAG stock price prediction model matches the current Hemab Therapeutics Holdings Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $45.19 (+1.85%). The 1-week path is $46.13 (+3.96%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

¿Debería comprar acciones de Hemab Therapeutics Holdings Inc?

Currently, Hemab Therapeutics (COAG) is trading at $44.84, significantly below the average analyst price target of $60, indicating potential upside. However, the stock has a low RSI of 29.128, suggesting it is oversold, but it also reported a wider Q2 loss of $24.2 million, which raises concerns about its financial health. Therefore, while there is potential for recovery, the current financial losses and market volatility suggest a cautious approach.

COAG cerró en $44.37 el Thursday, tras bajar -0.74%

Hemab Therapeutics Holdings Inc (COAG) last closed at $44.37, losing -0.74%. These facts feed the 1-day and 1-week COAG price prediction above.

Factores de la previsión

Los factores de la previsión de Hemab Therapeutics Holdings Inc (COAG) combinan patrones gráficos similares, estacionalidad y medias móviles.

Similar patterns

Positive

Bullish

Seasonality

Positive

Bullish

SMA 20

Negative

Bearish

SMA 200

Positive

Bullish

Patrones gráficos similares

Acciones cuya trayectoria reciente más se parece a la de COAG, ordenadas por similitud.

Análisis de estacionalidad de COAG

Loading chart…

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis